BioMimetix
Greg Kunst boasts extensive experience in the biotech and healthcare industries, currently serving as Chairman of the Board of Directors at BioMimetix and as a Strategic Advisor at Epoch Biotech and OCULOGICA. Kunst holds board positions at FELIQS and Pr3vent INC, providing independent guidance to various venture-backed startups. Notably, Kunst founded Aurion Biotech, leading the company from inception to a significant workforce and securing over $200 million in venture financing. Previous roles include Vice President of Global Marketing and Market Access at Glaukos Corporation and Global Marketing Director positions at Alcon, where Kunst drove key business initiatives and global product launches. Educational credentials include a B.S. in Economics from Brigham Young University and an MBA from Vanderbilt University.
This person is not in any teams
This person is not in any offices
BioMimetix
BioMimetix is a pioneering small biotechnology firm at the forefront of transforming the landscape of cancer treatment with our novel compound, BMX-001. Leveraging groundbreaking research, we have developed a redox-active compound poised to revolutionize cancer treatment.